Expect negligible price impact from this administrative delisting. Monitor whether the consolidation actually improves QNTM's Nasdaq trading volumes over the coming months. Also watch for any Nasdaq compliance issues — the company flagged risk of failing minimum bid price requirements in the forward-looking statements.
Price Chart
Executive Summary
Quantum BioPharma (QNTM) announced it has applied for a voluntary delisting from the Canadian Securities Exchange (CSE), citing insufficient trading volume to justify the costs of a dual listing. The company will continue trading on Nasdaq and expects the last CSE trading day to be September 4, 2026, subject to CSE approval. This is a routine administrative move with no impact on Nasdaq listing or fundamentals, but it may reduce shareholder liquidity for Canadian holders.
Key Facts
- Quantum BioPharma voluntarily applied to delist its Class B shares from the CSE.
- Last expected trading day on the CSE is September 4, 2026, subject to CSE approval.
- The delisting does not affect the company's Nasdaq, Frankfurt Stock Exchange, or Upstream listings.
- Management stated the move consolidates trading into a single principal marketplace on Nasdaq, which they expect may benefit long-term liquidity.
- The company will remain a Canadian reporting issuer and continue filing on SEDAR+ and EDGAR.
- No shareholder action is required; Canadian shareholders are directed to contact brokers regarding trading on Nasdaq.
Financial Impact
No material financial impact — cost savings from eliminating a low-volume dual listing.
Risk Factors
- Risk that the CSE does not approve the delisting or approves it on different terms.
- Risk that Nasdaq delisting requirements, including minimum bid price, are not met in the future, leaving the stock without a principal exchange.
- Canadian shareholders may face additional costs or settlement delays when switching to Nasdaq trading.
- Reduced market visibility or analyst coverage in Canada could negatively affect liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers